Compare Prospect Capital Corporation (PSEC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Prospect Capital Corporation trades at $1.72 (market cap $974.22M), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 130.9× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PSEC | VRTX | |
|---|---|---|
Market Cap | $974.22M | $127.55B |
Volume | 5,779,996 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $3.05 | $557.96 |
52-Week Low | $1.82 | $407.37 |
Typical Hold Time | 78 Days | 120 Days |
Enterprise Value | $2.73B | $121.68B |
Dividend Yield | 23.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.82, down 1.09% today, with a bearish technical outlook from moving averages. The company shows mixed fundamentals with a low P/B of 0.33 but concerning revenue volatility, including a -$407M revenue in 2025. Recent quarterly EPS has consistently beaten expectations, and the company maintains regular dividend distributions. Analyst sentiment is cautious with 55% hold ratings, while technical indicators show oversold conditions with RSI below 10.
PSEC presents a high-risk opportunity with a discounted valuation and strong dividend yield, but faces significant challenges from volatile revenue performance and negative cash flow. The stock's current technical weakness and mixed analyst consensus suggest cautious approach required despite attractive yield characteristics.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
